Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Star Combo PharmaASX:S66 35 EV-to-FCF is 0.63 as of Aug. 02, 2026. GuruFocus rates ASX:S66 with a GF Score™ of 35/100 and a GF Value™ of A$0.13 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,192 Consumer Packaged Goods companies, Star Combo Pharma ranks better than 98.49% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Star Combo Pharma's Enterprise Value is A$3.82 Mil.
Star Combo Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$6.04 Mil. Therefore, Star Combo Pharma's EV-to-FCF for today is 0.63.
The historical rank and industry rank for Star Combo Pharma's EV-to-FCF or its related term are showing as below:
ASX:S66'
s EV-to-FCF Range Over the Past 10 Years
Min: -19.79 Med: -4.82 Max: 1.83
Current: 0.41
During the past 9 years, the highest EV-to-FCF of Star Combo Pharma was 1.83. The lowest was -19.79. And the median was -4.82.
ASX:S66's EV-to-FCF is ranked better than 98.49% of 1192
companies
in the Consumer Packaged Goods industry
Industry Median: 16.01
vs ASX:S66: 0.41
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Star Combo Pharma's PE Ratio (TTM) for today is calculated as:
Star Combo Pharma's share price for today is A$0.13.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Star Combo Pharma's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.040.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Star Combo Pharma EV-to-FCF Related Terms
Star Combo Pharma EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Star Combo Pharma's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Household & Personal Products subindustry, Star Combo Pharma's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Star Combo Pharma EV-to-FCF vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Star Combo Pharma's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Star Combo Pharma's EV-to-FCF falls into.
Star Combo Pharma's current Enterprise Value is A$3.82 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Star Combo Pharma's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was A$6.04 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Star Combo Pharma (ASX:S66) has a EV-to-FCF of 0.63 as of Aug. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Star Combo Pharma and its competitors. According to the industry distribution chart, Star Combo Pharma ranks #18 out of 1192 companies in the Consumer Packaged Goods industry, placing it in the top 1.5%.
Is Star Combo Pharma's EV-to-FCF too high?
Star Combo Pharma's current EV-to-FCF is 0.63. The Consumer Packaged Goods industry median EV-to-FCF is 16.01. Star Combo Pharma's value of 0.63 is 96.1% below this industry median. Based on the distribution chart, Star Combo Pharma ranks #18 out of 1192 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Star Combo Pharma has a GF Score™ of 35/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Star Combo Pharma's EV-to-FCF compare to PG and CL?
According to the Consumer Packaged Goods industry distribution chart, Star Combo Pharma ranks #18 out of 1192 companies for EV-to-FCF. This places Star Combo Pharma in the top 2% of its industry — outperforming the majority of peers. The industry median EV-to-FCF is 16.01. Star Combo Pharma's value of 0.63 is 96.1% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Consumer Packaged Goods company?
The median EV-to-FCF among Consumer Packaged Goods companies is 16.01, based on 1,192 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Star Combo Pharma's current EV-to-FCF of 0.63 is 96.1% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Star Combo Pharma and its competitors. For the Consumer Packaged Goods industry, the median EV-to-FCF is 16.01 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Star Combo Pharma's current EV-to-FCF is 0.63. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Star Combo Pharma stock overvalued right now?
Based on GuruFocus' analysis, Star Combo Pharma (ASX:S66) is currently considered Fairly Valued. The stock's GF Value™ is A$0.13, compared to a current price of A$0.13 — trading right at its estimated fair value. The current EV-to-FCF is 0.63 and 96.1% below the Consumer Packaged Goods industry median of 16.01. Star Combo Pharma's overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Star Combo Pharma (ASX:S66), the current EV-to-FCF is 0.63 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Star Combo Pharma (ASX:S66) Overvalued in 2026?
Based on GuruFocus' analysis, Star Combo Pharma stock appears to be undervalued.
The current stock price of A$0.13 is trading 0% below its estimated GF Value™ of A$0.13.
GuruFocus considers Star Combo Pharma to be Fairly Valued.
Key valuation signals for ASX:S66:
EV-to-FCF: 0.63
GF Value™: A$0.13 vs. price of A$0.13 (0% below fair value)
Industry Position: 96.1% below the Consumer Packaged Goods median (#18 of 1192)
No single metric tells the full story. See the ASX:S66 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Star Combo Pharma Ltd is engaged in the manufacturing and distribution of food products and nutritional supplements. The company offers products such as Costar, Living Healthy, Amax, and J&K. It operates in two segments. The Star Combo segment engages in the development, manufacturing, marketing, and sales of natural health supplements and skincare products. The Austoyou retail business segment consists of the Australia-China e-commerce platform that offers product lines directly to Chinese health product consumers, and Koala Mall's two retail stores in Sydney. Geographically, it operates in China and Australia.
35GF Score
Get the complete analysis for ASX:S66
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:S66 has been successfully added to your 
